Exploratory Analysis of Plasma Protein Abundance Kinetics from I-SABR, A Randomized Phase II Trial of Stereotactic Ablative Radiotherapy with or without Nivolumab in Stage I-IIA or Recurrent Non-Small Cell Lung Cancer